In an endeavour to facilitate whole vaccine development process right from manufacturing, licensing to launching the final product in the market, the government has launched ‘Mission Covid Suraksha’. The mission would help accelerate the development of approximately 5-6 vaccine candidates and ensure that these are brought closer to licensure and introduction in the market, the Department of Biotechnology said on Wednesday.

As per a PTI report, the mission envisages Covid-19 vaccine development with end-to-end focus from preclinical through clinical development and manufacturing and regulatory facilitation. Earlier this month, the government had announced a package of Rs 900 crore for vaccines.

Also read: ‘Delhi schools unlikely to reopen until covid-19 vaccine available’

“Government of India (GOI) announced the third stimulus package of Rs 900 crore for the Mission Covid Suraksha- the Indian Covid-19 Vaccine Development Mission. This grant will be provided to the Department of Biotechnology (DBT) for research and development of Indian Covid-19 vaccines. “This will help accelerate development of approximately five-six vaccine candidates and ensure that these are brought closer to licensure and introduction in the market for consideration of regulatory authorities for introduction in public health systems to combat further spread of Covid infection,” the DBT was quoted saying by the report.

Earlier, the DBT had announced programmes for vaccine development and other Covid-related solutions, but this mission will be dedicated purely for development of vaccines, a DBT official said. A total of 10 vaccine candidates have been supported by the DBT so far in both academia and industry.

As on date, five vaccine candidates are in human trials, including the Russian Vaccine Sputnik-V, with at least three more in advanced stages of pre-clinical to enter human trials shortly.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.